Willow Biosciences Inc (TSE:WLLW) has released an update.
Willow Biosciences Inc. has sealed its largest deal yet, entering a multi-product development and licensing partnership with Laurus Labs for the manufacturing of active pharmaceutical ingredients (APIs). The agreement leverages Willow’s AI-driven bioengineering platform to create sustainable, cost-effective API production processes, with the first commercial products expected by 2025. Willow anticipates significant revenue from R&D payments and future royalties on worldwide sales, marking a major step in their expansion into the pharmaceutical sector.
For further insights into TSE:WLLW stock, check out TipRanks’ Stock Analysis page.
